Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | FABP2 | P12104 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507009 | 0.88 | USP30 (0.43) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL4150745 | 0.88 | USP30 (0.43) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL3269495 | 0.84 | PIK3CD (0.47) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL1273077 | 0.84 | HTR6 (0.49) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL19179939 | 0.84 | PIK3CA (0.42) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL6022262 | 0.83 | TUBB1 (0.44) | FABP4MCL1FABP3FABP2FABP5 | |
| SCHEMBL14865810 | 0.83 | PIK3CD (0.44) | PIK3CAPIK3CDABL1EGFRHCK | |
| Methane SCHEMBL6390810 | 0.82 | HTR6 (0.48) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL819797 | 0.82 | PIK3CD (0.46) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL312329 | 0.82 | PIK3CD (0.51) | PIK3CAPIK3CDABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4678632-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20250346557-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2025-11-13 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4642450-A2 | EP2 ANTAGONIST COMPOUNDS | Reservoir Neuroscience, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-5635197-A | BENZO(F)QUINOLIN-3-ONES; ANTICARCINOGENIC AGENTS; BONE DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| US-5629007-A | USING BENZOQUINOLIN-3-ONE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| US-5622961-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5622962-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| CN-1138458-A | Treatment and prevention of prostatic cancer | LILLY CO ELI (US) | 1996-12-25 | — | — | CN | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | PIK3CA 2377/4885PIK3CD 1749/4885ABL1 3859/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | PIK3CA 2223/4885PIK3CD 3891/4885ABL1 342/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | PIK3CA 1614/4885PIK3CD 2182/4885ABL1 252/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | PIK3CA 2650/4885PIK3CD 2190/4885ABL1 1/4885 |
| US-20250346557-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | STS, TST, CYP3A5 | PIK3CA 3185/4885PIK3CD 3755/4885ABL1 101/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | PIK3CA 1932/4885PIK3CD 3398/4885ABL1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.